Aqualung Therapeutics Corporation Receives A $2.3 Million National Institute Of Health (NIH) Fast-Track Award To Develop A Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury

KEY ACTIVITIES & PRESS

Jun 2

Written By Rebecca Nunn

READ PRESS RELEASE

6.2.2020

AwardsHome

Rebecca Nunn

Why An Experimental Therapy for Inflammatory Disorders Could Help the Fight Against COVID-19

AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS…